Please try another search
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Andrew Cheng | 54 | 2018 | President, CEO & Director |
Mark T. Iwicki | 55 | 2018 | Independent Chairman of the Board |
Jane Pritchett V. Henderson | 55 | 2019 | Independent Director |
Tomas J. Heyman | 65 | 2020 | Independent Director |
Graham Gordon Walmsley | 36 | 2018 | Independent Director |
Seth L. Harrison | 62 | 2019 | Independent Director |
Yuan Xu | 54 | 2021 | Independent Director |
Judy Chou | - | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review